ArticleTranslational pediatrics2025
Up-regulated vitronectin in Kawasaki disease shock syndrome serves as a potential biomarker.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kawasaki disease shock syndrome (KDSS) pathogenesis involves an immune inflammatory response related to Kawasaki disease (KD) that damages microvessel endothelial cells, leading to microcirculatory disorders. Its clinical manifestations are characterized by hypotension, poor peripheral perfusion, and a high risk of coronary artery lesions (CALs). Currently, there are few reports on biomarkers based on endothelial cell dysfunction in KDSS. This study aims to identify potential biomarkers of endothelial dysfunction in KDSS at the protein level. Methods: In this study, we recruited age- and sex-matched participants, consisting of KDSS patients, KD patients, and healthy control (HC) children. The inflammatory indicators and cytokines were compared between the KD and KDSS groups. The endothelial barrier function was assessed by dynamically measuring the cell impedance in human coronary artery endothelial cells (HCAECs). Tandem mass tag (TMT)-based proteomics was used to profile the differentially expressed proteins (DEPs) in KDSS plasma. Function and pathway enrichment analyses were performed for related pathways involved in KDSS pathology. Key proteins were validated through Western blotting. Results: Inflammatory cytokines were significantly higher in the KDSS group than in the KD group, and included interleukin-6 (IL-6) (259.37±385.20 Conclusions: This study provides a potential plasma proteomic profile for KDSS. Vitronectin may serve as a pathogenesis-based diagnostic biomarker for KDSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.